View Financial HealthMedicure 배당 및 자사주 매입배당 기준 점검 0/6Medicure 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026공시 • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada공시 • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025공시 • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025공시 • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025공시 • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada공시 • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.공시 • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024공시 • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.공시 • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.공시 • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024공시 • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.공시 • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023공시 • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MCUJ.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MCUJ.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Medicure 배당 수익률 vs 시장MCUJ.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MCUJ.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (MCUJ.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MCUJ.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MCUJ.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MCUJ.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MCUJ.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 22:55종가2026/05/12 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medicure Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andre UddinResearch Capital CorporationRobert GibsonVentum Financial Corp
공시 • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026
공시 • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada
공시 • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025
공시 • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025
공시 • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025
공시 • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada
공시 • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.
공시 • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024
공시 • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.
공시 • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.
공시 • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024
공시 • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.
공시 • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023
공시 • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.